Zydus Lifesciences announced that the safety and efficacy analysis data from the phase-III clinical trial of its Covid-19 vaccine ZyCoV-D has been examined and published in The Lancet, a reputed and well known medical journal.
The clinical trial of ZyCoV-D was one of the most significant trials for a Covid-19 vaccine in India. It was conducted on more than 28,000 adult volunteers at over 50 sites. The vaccine has shown good stability at a temperature of 25 degrees C for at least three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine and lower any cold chain breakdown challenges.

• Stocks Under F&O Ban: National Aluminium, PVR Inox, Granules India, and Others
• Income Tax Refund Grew 46% in April-November 
• Inventurus Knowledge Solutions Ltd IPO GMP, Lot Size, Key Dates & Investing Details
• Swiss National Bank Cuts Interest Rate by 50 Basis Points 
• SolarSquare Secures $40 in Series B Funding Round 

According to Zydus, the plug-and-play technology of the vaccine allows it to adapt to the SARS COV-2 virus. The trial was done during the peak of the second wave of the Covid-19 virus. The effectiveness of the vaccine stood at 66.6 per cent against the Delta Variant.